TRIMETAZIDINE MB ROLE IN THE OPTIMISATION OF THE ACUTE CORONARY SYNDROME TREATMENT: EFFECTS ON ENDOTHELIAL DYSFUNCTION AND SYSTEMIC INFLAMMATION

Aim. To study the effects of trimetazidine MB therapy on the clinical manifestations and markers of endothelial dysfunction and systemic inflammation in patients with acute coronary syndrome (ACS). 

Material and methods. This open, comparative, randomised parallel-group study included 60 patients with a verified ACS diagnosis (34 men and 26 women, aged 40–84 years). All participants were randomised into two treatment groups: the main group receiving trimetazidine MB (PreductalMB) 35 mg twice a day, and the control group receiving standard therapy but not trimetazidine MB. The examination included electrocardiography (ECG), echocardiography, 24-hour ECG monitoring, and chest X-ray. 

Results. After 3 months of the treatment, the main group demonstrated a significant reduction in the incidence and duration of anginal attacks (–58% and –42%, respectively), as well as in the weekly nitrate intake (–66%). There was a nonsignificant (possibly, due a relatively small sample size) tendency towards a reduction in the severity of anginal attacks (–36%). The control group demonstrated a less prominent dynamics of clinical parameters: the incidence of anginal attacks decreased by 21%, the weekly nitrate intake by 20%, and the duration and severity of anginal attacks only by 6%. 

Conclusion. The combination of trimetazidine MB with the standard ACS therapy improves the treatment effectiveness, in terms of the anginal syndrome manifestations and endothelial function stabilisation, as suggested by a significant reduction in von Willebrand factor and endothelin levels, compared to the control group.

1. Serkova V. K. Metabolic cardiocytoprotection in treatment of patients with IHD: role of partial inhibitors of fatty acid oxidation. Rational pharmacotherapy. 2008;1:26–29. (Серкова В. К. Метаболическая кардиоцитопротекция в терапии больных ишемической болезнью сердца: роль парциальных ингибиторов окисления жирных

2. кислот. Рациональная фармакотерапия. 2008;1:26–29).

3. Chen YD, Zhao LK, Tian F, et al. Evaluation of the myocardial protection of trimetazidine during percutaneous coronary intervention: a multi-center randomized and controlled clinical study. Zhonghua Nei Ke Za Zhi. 2010;49 (6):473–6.

4. Morosova T. E. Metabolic medicine in cardiological practice. Lechaschii vrach. 2008;6:48–51. (Морозова Т. Е. Метаболические лекарственные вещества в кардиологической практике. Лечащий врач. 2008;6: 48–51).

5. Yao J, Jiang SL, Liu W, et al. Tissue inhibitor of matrix metalloproteinase-3 or vascular endothelial growth factor transfection of aged human mesenchymal stem cells enhances cell therapy after myocardial infarction. Rejuvenation Res. 2012;15 (5):495–506.

6. Vasyuk Yu.A. Kulikov K. G. Kudryakov O. N. Mitochondrial dysfunction

7. in pathogenesis of acute myocardial infarction: principles of diagnostics and

8. treatment by myocardial cytoprotectors. Russian Medical News, 2008;8 (2):10–18.(Васюк Ю. А., Куликов К. Г., Кудряков О. Н., Крикунова О. В. Митохондриальная дисфункция в патогенезе острого инфаркта миокарда: принципы диагностики и терапии миокардиальными цитопротекторами. Российские Медицинские Вести. 2008;8 (2):10–18).

9. Schelbert EB, Cao JJ, Sigurdsson S, et al. Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults. JAMA. 2012;308 (9):890–6.

10. Chen YD, Zhao LK, Tian F, et al. Evaluation of the myocardial protection of trimetazidine during percutaneous coronary intervention: a multi-center randomized and controlled clinical study. Zhonghua Nei Ke Za Zhi. 2010;49 (6):473–6.

11. Valensi P, Lorgis L, Cottin Y, et al. Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: a review of the literature. Arch Cardiovasc Dis. 2011;104 (3):178–88.

12. Aronov D. M. Lupanov V. P. Atherosclerosis and CHD. Second edition. Moscow, Triada-X, 2009. (Аронов Д. М., Лупанов В. П. Атеросклероз и коронарная болезнь сердца. —2-е изд., перераб. М.: ТРИАДА–Х, 2009 г.)

13. Ammirati E, Cannistraci CV, Cristell NA, et al. Identification and predictive value of interleukin-6+ interleukin-10+ and interleukin-6- interleukin-10+ cytokine patterns in ST-elevation acute myocardial infarction. Circ Res. 2012;111 (10):1336–48.

14. Chen WY, Lee RT. Endothelial cardiac cell therapy: large-animal studies and the elephant in the room. Circ Res. 2012;111 (7):824–6.

15. Damani S, Bacconi A, Libiger O, et al. Characterization of circulating endothelial cells in acute myocardial infarction. Sci Transl Med. 2012;4 (126):126–33.

16. Park KH, Park WJ, Kim MK, et al. Effects of trimetazidine on endothelial dysfunction after sheath injury of radial artery. Am J Cardiol. 2010;105 (12):1723–7.

17. Kiseleva M. S. Davydov S. I. Titova V. V. Proinflammatory cytokines as markers of system inflammation in patients with acute coronary syndrome. Messenger VolgSMU. 2010:9–11. (Киселева М. С., Давыдов С. И., Титова В. В. Провоспалительные цитокины как маркеры системного воспаления у больных острым коронарным синдромом. Вестник ВолгГМУ. 2010: 9–11).

18. Zhou X, Li C, Xu W, Chen J. Trimetazidine protects against smoking-induced left ventricular remodeling via attenuating oxidative stress, apoptosis, and inflammation. PLoS One. 2012;7 (7):404–24.